Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Philadelphia positive acute lymphoblastic leukemia treatment has been driven…
Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic In the phase…
On January 27, 2023, the U.S. Food and Drug Administration approved elacestrant for postmenopausal, non-pregnant women and adult men with…
On January 27, 2023, the U.S. Food and Drug Administration approved Pirtobrutinib for adult patients with histologically confirmed relapsed or…
By Luke Fletcher, MD Willamette Valley Cancer Institute & Research Center Imetelstat, a telomerase inhibitor, has shown interesting promise…
On January 26, 2023, the U.S. Food and Drug Administration approved Pembrolizumab for patients with resectable, stage IB (≥4cm)-IIIA (as…
By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School "Overall, a major shift in the way we treat breast…
On January 19, 2023, the U.S. Food and Drug Administration granted accelerated approval to Tucatinib plus Trastuzumab for adult patients…
Janakpurdham, Nepal, April 27, 2022 – The Binaytara Foundation hosted its Fourth International Cancer Congress on April 16, bringing together…
Oncologists Interested in Improving Access to Cancer Care Encouraged to Apply Are you an oncologist who is passionate about educating…